Trial comparing D-penicillamine and gold in rheumatoid arthritis

Preliminary report*

E. C. HUSKISSON, T. J. GIBSON, H. W. BALME, H. BERRY, H. C. BURRY, R. GRAHAME, F. DUDLEY HART, D. R. F. HENDERSON, AND J. A. WOJTULEWSKI

From the Department of Rheumatology, St. Bartholomew's Hospital; Guy's Arthritis Research Unit; and the Department of Rheumatology, Westminster Hospital, London

The Multicentre Trial Group (1973) showed that penicillamine was superior to placebo in a double-blind trial against placebo. In this trial penicillamine was compared with gold.

There are three reasons why a double-blind trial of penicillamine and gold was not attempted; first, gold is given by injection and penicillamine orally; secondly, both drugs have distinctive side effects which might 'unblind' the observer; and thirdly, because some side effects are potentially dangerous, it is essential that the physician knows which drug his patient is receiving. For these reasons, the patients were treated by their usual physicians who supervised dosage and documented side effects. Before the trial and at 3-monthly intervals after the start of treatment, the patients were seen by a 'blind' observer from another hospital.

Methods

Eighty-nine patients from three centres were admitted to the trial. All had definite or classical rheumatoid arthritis by the A.R.A. criteria (Committee of the American Rheumatism Association, 1959) of at least 6 months' duration, with an articular index (Ritchie, Boyle, McInnes, Jasani, Dalakos, Grieverson, and Buchanan, 1968) of at least eight, and an ESR of at least twenty-five. All were outpatients.

Patients were allocated to treatment with either gold or penicillamine according to a randomized schedule stratified for age, sex, steroid therapy, and type of anti-inflammatory drug therapy. As far as possible, patients were given aspirin alone; when this was not possible, they were given one other drug only; phenylbutazone was not permitted and patients who had received either gold or penicillamine in the past were excluded.

Gold was given in the form of sodium aurothiomalate (Myocrisin) in a dose of 10, 20, 30, and 40 mg weekly for the first 4 weeks, then 50 mg weekly up to a total dose of

1g, then 50 mg monthly. Penicillamine was given in an initial dose of 250 mg daily of base or 300 mg, daily of hydrochloride, increasing by 250 mg or 300 mg, respectively, every fortnight up to a total dose between 1 and 1.8 g daily according to response.

The following measurements were made before the start of treatment and at 3-monthly intervals thereafter: pain using a visual analogue scale; duration of morning stiffness; an assessment of progress (worse, unchanged, slightly, moderately, and much better); joint size (Boardman and Hart, 1967); grip strength; articular index (Ritchie and others, 1968); nodule count; ESR; latex test; sheep cell agglutination test.

Clinical measurements were made by two observers and all measurements of a particular patient were made by the same observer. The observer did not know which treatment the patient was receiving and patients were asked not to discuss their treatment or their side effects with the observer.

The results were analysed by Student's t-test; this was applied to differences between measurements at the start of the trial and after 3 and 6 months of treatment. Differences within treatment groups were analysed by Student's t-test applied to paired data. Correlation coefficients were used to examine relationships between different measurements and their significance tested by Student's t-test.

Results

Eighty-six patients completed at least 3 months' treatment. Three who were withdrawn in the first 3 months of the trial have not been included in the following analysis because no assessments were carried out; two were withdrawn for reasons unrelated to treatment, and one was unable to tolerate even one tablet of penicillamine.

Table I shows that the forty patients receiving gold and forty-six receiving penicillamine were well matched for sex, age, and duration of rheumatoid

Accepted for publication May 5, 1974.

* Based on a paper read at the Heberden Society in November, 1973.

Address correspondence to Dr. E. C. Huskisson, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE.

Table I Characteristics of patients receiving either gold or penicillamine

	Gold	Penicillamine
Number	40	46
Male: female	12:28	17:29
Age (yrs)	51.9	52.4
Duration of disease (yrs)	6.0	5.0

There are no significant differences between the groups.

arthritis. There was no statistically significant difference between the groups in any of these respects, nor in any of the initial measurements, which are shown in Tables II and III.

Tables II and III show the changes in various measurements made after 3 and 6 months' treatment. All have been analysed using Student's t-test applied to differences between measurements at 3 or 6 months and those made before the start of the trial. In no case was a significant difference found between the effects of the two drugs.

Student's t-test was also applied to changes within each treatment group. There were statistically highly significant improvements in all measurements at 3 months with both drugs. Between 3 and 6 months there were further highly significant improvements in grip strength and latex titre with both drugs, joint size in patients receiving gold, and articular index in patients receiving penicillamine; there were significant improvements in pain in patients receiving

penicillamine and articular index in patients receiving gold. Most of the clinical improvement in both groups was achieved in the first 3 months of treatment.

There was a statistically significant reduction in the number of nodules after 6 months treatment with both drugs (Table IV).

Although a reduction in rheumatoid factor titres seems to be a feature of therapy with these drugs, there was no evidence that this reduction played any part in the therapeutic response. Fig. 1 shows that there was no significant correlation between changes in latex titre and pain relief in patients receiving penicillamine ($r = 0.0$; $P > 0.1$). Fourteen patients who were seronegative at the start of the trial obtained pain relief of similar degree to the remaining seropositive patients ($t = 0.14$; $P > 0.1$). There was no evidence that response was related to age ($r = 0.14$; $P > 0.1$), or duration of arthritis ($r = 0.10$; $P > 0.1$).

Table V shows withdrawals from the trial in the first 6 months and these were significantly more frequent in patients receiving gold than in those receiving

Table IV Changes in number of rheumatoid nodules after 6 months' treatment with penicillamine or gold

	Total No. of patients	Increased	Decreased	Sign test
Gold	9	0	6	$P = 0.032$
Penicillamine	15	1	10	$P = 0.012$

Table II Mean initial levels and changes in clinical measurements after 3 and 6 months' treatment with penicillamine (P) or gold (G)

Months of treatment	Pain		Duration of morning stiffness		Articular index		Grip strength		Joint size	
	G	P	G	P	G	P	G	P	G	P
0	14.2	14.1	104.5	99.6	23.6	25.8	228.0	216.0	585.3	587.7
3	+6.3	+6.2	+52.8	+48.8	+10.4	+11.6	+47.3	+40.0	+11.2	+12.2
6	+6.3	+7.7	+59.9	+60.6	+11.8	+14.1	+82.4	+80.8	+19.9	+17.4

+ Figures indicate improvement.

Table III Mean initial levels and changes in laboratory measurements after 3 and 6 months' treatment with penicillamine or gold

Months of treatment	ESR		Latex*		SCAT†	
	G	P	G	P	G	P
0	52.2	52.9	4.0	4.5	3.6	4.5
3	+15.7	+21.5	+1.2	+1.1	+1.1	+1.5
6	+28.7	+23.7	+1.5	+1.8	+1.4	+2.0

* Titres were scored: 1 = $<1/20$; 2 = $1/20$; 3 = $1/40$, etc.

† 1 = $<1/16$; 2 = $1/16$; 3 = $1/32$, etc.

+ Figures indicate improvement.

FIG. 1 *Lack of relationship between pain relief and changes in latex titre in patients receiving penicillamine*

Table V *Withdrawals in first 6 months of treatment*

	Drop-out	Survivors	Total
Gold	14	25	39
Penicillamine	3	40	43
Total	17	65	82

The difference between the gold and penicillamine groups is highly significant ($\chi^2 = 10.3$; $P < 0.01$).

penicillamine. Rashes or pruritus accounted for twelve of the fourteen gold withdrawals. Two patients receiving gold and two receiving penicillamine were withdrawn because of heavy proteinuria or nephrotic syndrome. One patient receiving penicillamine was withdrawn because of nausea and vomiting. Four patients were withdrawn for reasons unrelated to treatment.

Fig. 2 shows the incidence of clinically important side effects and it is clear that there is a large excess of these attributable to penicillamine in the first 2 months of treatment. Of these side effects, rashes (Fig. 3) occurred in 32.5% of patients receiving gold and in 24% of those receiving penicillamine. The penicillamine rashes occurred earlier and in no case caused withdrawal of treatment for more than a week or two. All but one of the patients receiving gold who developed rashes were withdrawn; gold therapy was restarted in this patient, but the rash recurred after 3 months. Apart from rashes and two cases of heavy proteinuria, no other important side effects were noted in patients receiving gold.

Fig. 4 shows the incidence of some other side effects

FIG. 2 *Number of patients developing side effects while receiving either penicillamine or gold*

FIG. 3 *Number of patients developing rashes while receiving either penicillamine or gold*

of penicillamine. Loss of taste occurred in 24% of patients during the first 3 months of the trial, lasted 4–8 weeks, and did not necessitate withdrawal of treatment. Gastrointestinal disturbances occurred in 33% of patients, also commonly in the first 3 months of treatment, with nausea and anorexia being the commonest symptoms. 27% of these episodes were associated with loss of taste. In the 4th, 5th, and 6th months, six patients (13%) developed thrombocytopenia with levels between 46,000 and 110,000 platelets/mm³; in one case this was associated with haemoptysis and in another with haematuria. In all cases, the platelet count returned rapidly to normal with prompt withdrawal of penicillamine and treatment was later restarted at a lower dose. Transient slight proteinuria was common in patients receiving

FIG. 4 Number of patients developing loss of taste, gastrointestinal disturbance, or thrombocytopenia while receiving penicillamine

both drugs, but did not necessarily herald the development of serious proteinuria.

Discussion

On present evidence, there is little to choose between penicillamine and gold therapy in the management of patients with active rheumatoid disease which has failed to respond to simpler measures; in the first 6 months of treatment, gold and penicillamine were equally effective. Gold treatment had to be withdrawn much more frequently than penicillamine because of rashes which occurred in about one third of cases. However, there were more side effects on penicillamine, particularly loss of taste, rashes, gastrointestinal disturbance, and thrombocytopenia; these were usually transient and did not prevent the continuation of treatment. The incidence of heavy proteinuria was equal in the two groups, but since penicillamine nephropathy is commonly encountered after 9 months of treatment, more cases may be expected in the next 6 months of the trial.

Summary

In the first 6 months of a comparative study in patients with rheumatoid arthritis, penicillamine and gold were equally effective. Penicillamine caused more side effects but the side effects which occurred in patients receiving gold were more likely to require withdrawal of treatment.

References

- BOARDMAN, P. L., AND HART, F. D. (1967), *Brit. med. J.*, **4**, 264 (Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis)
- COMMITTEE OF THE AMERICAN RHEUMATISM ASSOCIATION (1959) *Ann. rheum. Dis.*, **18**, 49 (Diagnostic criteria for rheumatoid arthritis: 1958 revision)
- MULTICENTRE TRIAL GROUP (1973) *Lancet*, **1**, 275 (Controlled trial of D-penicillamine in severe rheumatoid arthritis)
- RITCHIE, D. M., BOYLE, J. A., MCINNES, J. M., JASANI, M. K., DALAKOS, T. G., GRIEVESON, P., AND BUCHANAN, W. W. (1968) *Quart. J. Med.*, **37**, 393 (Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis)